12:11 PM
Oct 26, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has missed its primary endpoint. Lundbeck reported that Lu AF35700 missed the primary endpoint in the Phase III DAYBREAK trial for treatment-resistant schizophrenia.

Dunsire become president and CEO on...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >